ArticleFrontiers in endocrinology2025
Triglycerides as a mediator in the hyperuricemia-diabetes link: insights from a hypertensive Chinese population.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of novel triglyceride-glucose index-derived indices with hyperuricemia among oilfield workers.Frontiers in nutrition · 2026Article
- Association between the Zhejiang University index and hyperuricemia among adults with type 2 diabetes in China.Frontiers in endocrinology · 2026Article
- Remnant cholesterol: an independent, dose-dependent risk factor for hyperuricemia in a normolipidemic chinese population.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates whether triglycerides mediate the association between hyperuricemia and Type 2 Diabetes Mellitus (T2DM) in a hypertensive Chinese population. By comparing individuals with and without diabetes and applying generalized structural equation modeling (GSEM), we aimed to clarify the indirect effects of hyperuricemia via triglyceride pathways. Methods: A total of 274 hypertensive diabetic patients were assessed for clinical and biochemical profiles. The study included clinical categorization of DM status, demographic analysis, generalized structural equation modeling (GSEM) for mediation analysis, and regression modeling to identify diabetes risk factors. Results: Diabetic individuals exhibited significantly higher triglyceride levels (P=0.005). Age ≥65 years was a notable demographic risk factor compared to those aged 32-49 years (OR=6.35, 95% CI: 1.26-31.97). Occasional smoking also increased DM risk (OR=3.92, 95% CI: 1.00-15.35), while alcohol consumption showed no significant association. Hyperuricemia was positively associated with elevated triglyceride levels (coefficient = 0.67, P=0.01), which, in turn, significantly increased DM risk (coefficient = 1.29, P < 0.001). Although the direct effect of hyperuricemia on DM was not statistically significant (coefficient = -0.61, P=0.10), the indirect effect mediated by triglycerides was substantial (coefficient = 0.87, P=0.04). BMI categorization significantly influenced both hyperuricemia and triglyceride levels, with the highest BMI category (≥27) exhibiting the greatest prevalence (60.26% and 38.46%, respectively). However, the direct association between BMI and DM was not statistically significant (P=0.407), suggesting the involvement of mediating factors. Conclusion: Triglycerides play a key mediating role in the relationship between hyperuricemia and Type 2 DM among hypertensive patients. BMI is significantly associated with hyperuricemia and triglyceride levels, although not directly with DM. These findings emphasize the need for targeted interventions focused on lipid regulation, weight control, and lifestyle modifications to prevent diabetes progression in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.